ArticleFrontiers in oncology2026
Case Report: Primary non-gestational small intestinal choriocarcinoma misdiagnosed as ectopic pregnancy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary small intestinal choriocarcinoma is an extremely rare nongestational malignancy associated with non-specific clinical manifestations and a high risk of misdiagnosis. Case presentation: A 40-year-old female presented with amenorrhea, vaginal bleeding, and elevated serum β-human chorionic gonadotropin (β-hCG). She was initially suspected of ectopic pregnancy and received emergency laparoscopic exploration. A 2×1 cm ileal tumor was resected, and histopathological testing verified choriocarcinoma. Given the intraoperatively normal pelvic viscera and postoperative imaging ruling out alternative primary tumors, primary small intestinal choriocarcinoma was confirmed. The patient attained complete biochemical remission after five cycles of FAV chemotherapy (fluorouracil, actinomycin D, vincristine), with serum β-hCG levels falling from 1336 mIU/mL to 0.23 mIU/mL. Thirteen months after FAV completion, biochemical relapse emerged, accompanied by pulmonary and right adnexal metastatic lesions. The adnexal lesion developed chemoresistance following nine cycles of EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) and only showed minimal response to two cycles of FAEV (fluorouracil, actinomycin D, etoposide, vincristine). Subsequent right adnexectomy was conducted, followed by two consolidation cycles of FAEV, which resulted in durable long-term remission. Conclusion: This case highlights a diagnostic pitfall in gynecological practice and suggests that multimodal therapy combining chemotherapy and surgery may achieve long-term disease control in refractory cases. Given the rarity of primary small intestinal choriocarcinoma, further molecular data are needed to validate these findings and refine therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.